Resistell AG closed a first tranche of its Series B financing round with CHF 8.5 million raised from new and existing investors. The startup is a leader in phenotypic nanomotion technology for measuring living cells. In April 2022, Resistell launched an R&D project to assess the applicability of its antibiotic susceptibility test (AST) to a novel antibiotic with independent funding provided by Pfizer.
